Telomerase activation through induction of its catalytic component telomerase reverse transcriptase (TERT) expression is essential for malignant transformation. TERT promoter mutations namely C228T and C250T that stimulate TERT transcription and telomerase activation have recently been identified in many human malignancies. We thus determined these mutations and their biological and clinical implications in thyroid carcinomas in the present study. The TERT promoter was sequenced in 10 thyroid cancer cell lines and 144 tumors from 20 patients with anaplastic thyroid carcinoma (ATC), 51 with papillary thyroid carcinoma (PTC), 36 with follicular thyroid carcinoma (FTC), and 37 with medullary thyroid carcinoma (MTC). We identified C228T or C250T mutation in 6/8 of ATC cell lines, as well as in tumor tissue from 10/20, 13/51, 8/36 and 0/37 patients with ATC, PTC, FTC and MTC, respectively. In PTC patients, these mutations were exclusively present in the group with age 445 years (Po0.0001), and highly correlated shorter telomeres (Po0.0001) and distant metastasis (P ¼ 0.028). The previous radioactivity exposure did not induce the mutation. The presence of C228T or C250T was an independent predictor associated with shorter disease-related survival (DRS) in the entire cohort (Po0.0001), as well as among patients 445 years (P ¼ 0.021). ATC patients carrying the mutation survived shorter than those without mutations, although not statistically significant (P ¼ 0.129). The TERT promoter mutation was associated with overall survival (P ¼ 0.038) and DRS (P ¼ 0.058) of FTC patients. Taken together, age-and shorter telomere-dependent TERT promoter mutations occur frequently in follicular cell-derived thyroid carcinoma (ATC, PTC and FTC) but not in parafollicular cell-originated MTC, and may serve as a marker for aggressive disease and poor outcome.
INTRODUCTION
Thyroid carcinoma is the most common malignancy of the endocrine system and its incidence and prevalence has significantly increased almost worldwide in the last decades. 1 Histopathologically, four main types of thyroid carcinoma are recognized: papillary, follicular, anaplastic and medullary (PTC, FTC, ATC and MTC, respectively). PTC, FTC and ATC are all derived from follicular thyroid cells, but differ significantly in genetic alterations, characteristics and clinical outcomes. 1 Both PTC and FTC are classified as differentiated thyroid cancer, whereas ATC is undifferentiated. Unlike PTC, FTC and ATC, MTC originate from parafollicular or C cells of the thyroid gland and displays distinct genetic alterations. 1 PTC and FTC in general have a good prognosis, but a small fraction shows aggressive behavior. ATC is highly aggressive and the majority of ATC patients survive less than 6 months. 1 Despite the identification of important genetic and epigenetic alterations essential for the pathogenesis of thyroid cancer in the past decade, the underlying molecular mechanisms remain incompletely understood and patients' survival has not substantially improved. Therefore, it is a demanding task to further define key molecular alterations driving the development and progression of thyroid cancer, thereby improving the diagnosis, outcome prediction and therapeutic efficacy.
Unlimited proliferation is a key hallmark of cancer including thyroid carcinoma. 2, 3 Many lines of evidence have demonstrated that activation of telomerase, a RNA-dependent DNA polymerase, is required for transformed cells to acquire an immortal phenotype during oncogenesis. [3] [4] [5] Telomerase is responsible for elongation of telomeric DNA at the termini of linear chromosomes and the stabilization of telomere length by telomerase contributes to infinite proliferation potential of malignant cells. [4] [5] [6] [7] It has been established that the transcriptional regulation of a rate-limiting catalytic component of the telomerase complex, telomerase reverse transcriptase (TERT), is a predominant determinant for controlling telomerase activity, and that telomerase activation occurring in malignant transformation results mainly from the de-repression of the TERT transcription. 5, 7 Therefore, elucidating how the TERT gene is transcriptionally activated in cancer cells has been one of the key study focuses in past years. Like many other human malignancies, thyroid cancer exhibits widespread telomerase activation and TERT induction, and the presence of telomerase activity and/or TERT expression has been tested as diagnostic and prognostic markers. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] More recently, a number of studies have shown that the TERT promoter mutation occurs in certain types of human malignancies and might be one of important mechanisms contributing to telomerase activation in those malignant cells. [22] [23] [24] [25] In the present study, we thus sought to address the following issues: (i) whether the TERT promoter mutation is present in thyroid cancer; and (ii) if so, whether the mutation can serve as a marker for disease progression and outcome prediction. Toward these ends, we sequenced the TERT promoter in the four major types of thyroid cancer (ATC, PTC, FTC and MTC), and explored the relationship between TERT promoter mutation and clinical parameters in them.
RESULTS
High frequency of the TERT promoter mutation in follicular thyroid cell-derived carcinomas and cell lines We screened 144 tumor specimens from thyroid cancer patients for the TERT promoter mutation. Representative sequencing chromatograms are shown in Figure 1b and the results are summarized in Table 1 and detailed in Supplementary Tables S1-S3 . Briefly, the observed frequencies of TERT promoter mutations (including both C228T and C250T) were 50% (10/20) for ATCs, 25% (13/51) for PTCs and 22% (8/36) for FTCs. C228T was the predominant form of mutation in all three types of thyroid cancer, accounting for 87% of the detected mutations (8/10 ATCs, 12/13 PTCs and 7/8 FTCs). In sharp contrast, none of 37 MTC tumors carried C228T or C250T mutation. Thus, the TERT promoter mutation only occurs in follicular cell-derived thyroid carcinomas. An identical analysis was also performed on eight ATC-and two MTC-derived cell lines (Supplementary Table S4 ). The sequencing results revealed that the TERT promoter mutation occurred in 75% (6/8) of the ATC cell lines, among which five were C228T and one was C250T (Table 1 and Supplementary Table S4 ). Consistent with the result obtained from primary MTC tumors, none of two MTC cell lines had the mutation (Table 1 and Supplementary Table S4 ).
Association of the TERT promoter mutation with age of PTC and FTC patients The age range of the 51 PTC patients at diagnosis was from 22 to 97 years old with a median age of 45 years. Among the 13 PTC patients with TERT promoter mutation, the youngest was 49 years old, far beyond the median age, and the remaining 12 patients were between 56 and 84. The mutation frequency was 52% (13/25) in PTC patients 445 years. The age difference was highly significant between patients with and without the mutation (Po0.0001; Table 2 and Supplementary Table S2 ). To further verify this correlation, we sequenced another cohort of young PTC patients (age range 19-39 years old with median 31) surgically treated at Kyiv City Teaching Endocrinological Center, Ukraine, and all these patients had been exposed to radioactivity from the accident at the Chornobyl nuclear power station in Ukraine in 1986. 26 Consistently, none of these 51 tumors carried the TERT promoter mutation. Taken together, the TERT promoter mutation is strongly age dependent in PTC.
One of eight TERT promoter mutation-positive FTC patients was 31 years old and the remaining were 445 years. The age range was 31-83 (median 69) and 17-77 (median 54) for FTC patients with and without TERT promoter mutation, respectively, and this difference reached a statistically significant level (Supplementary  Table S3 , P ¼ 0.05). All ATC patients were 450 years old (51-91 with median age 75) at the time of diagnosis and age-dependent TERT promoter mutation were not observed in this group (mutated vs wild type: 62-86 years with median 75 vs 51-91 years with median 76 years, P ¼ 0.704).
BRAF
V600E -independent TERT promoter mutation in PTC BRAF mutation is to date the most commonly detectable genetic event in PTC with a frequency of 30-70%. 1 We therefore screened for the presence of BRAF V600E in our PTC specimens to determine whether there exists a relationship between the BRAF mutation and age or between the two mutational events. We identified 32 BRAF V600E -positive tumors in 51 PTCs (63%). The presence of BRAF V600E was not associated with TERT promoter mutation (11/32 for BRAF V600E vs 2/19 for BRAF V600E wild type, Fisher exact test, P ¼ 0.11) or age (14/25 for p45 vs 18/26 for 445 years, P ¼ 0.285; Table 2 and Supplementary Table S2 ).
Correlation of shorter telomere with the TERT promoter mutation in PTC It is well established that very short telomere is a strong trigger for telomerase activation during cellular immortalization. We thus sought to determine the relationship between telomere length and the TERT promoter mutation in PTC patients. The mean telomere length was 0.873 ± 0.45 and 1.569 ± 0.627 for PTC patients with and without TERT promoter mutation, respectively, and was significantly shorter in the mutation group (Po0.0001; Figure 2a , and Table 2  and Supplementary Table S2 ). Because this mutation predominantly occurred in elderly PTC patients as documented above, we further examined whether telomere length in tumors was age related. The Pearson correlation analysis demonstrated that telomere length in PTC cancer cells was independent of patients' Relationship between the TERT promoter mutation and aggressive disease and patients' outcomes in thyroid cancer The results obtained from both cell lines and primary tumors, as described above, showed that the most aggressive carcinomas had the highest prevalence of the TERT promoter mutation in all tumor types, indicating a link between the mutation and progressive disease behaviors. Thus, we further asked whether this genetic event was associated with progression and patients' outcomes in each subtype. In ATC patients, there was no difference in tumor size and metastasis between the TERT promoter mutation-positive and -negative tumors (Supplementary Table S1 ). These patients all died of the disease except one and the patients with the mutation tended to have shorter overall survival (OS) than did those with wild-type TERT promoter (P ¼ 0.129; Supplementary Figure S1 ). In PTC, the presence of the TERT promoter mutation was strongly associated metastasis (7/11 for mutated vs 3/25 for wild type, Fisher exact test, P ¼ 0.028). Univariate analyses showed that TERT promoter mutation and age 445 years, but not BRAF V600E , were significantly associated with shorter OS (both Po0.0001, Figures 3a and b, and Table 2 ). On multivariate analysis, age445 years was significantly associated with shorter OS (Figure 3d , P ¼ 0.003), whereas patients carrying TERT promoter mutation stratified by age 445 years did not exhibit significantly shorter OS (P ¼ 0.416, Figure 3c ). However, an opposite result was obtained for disease-related survival (DRS). Both the presence of the TERT promoter mutation and age 445 years were significantly correlated with the disease-related death in PTC patients using univariate analysis (Po0.0001 and ¼ 0.015 for mutated TERT promoter and age445, respectively, Figures 3e and f), whereas the former, but not age 445 years, independently predicted a worse DRS, as revealed by multivariate analysis (Figures 3g and h , P ¼ 0.021 and 0.882 for the TERT mutated promoter and age 445 years, respectively). The presence of BRAF V600E was not associated with PTC OS or DRS (Table 2) . In FTC patients, there was no difference in metastasis and tumor size between the TERT promoter mutation-positive and -negative groups (Supplementary Table S3 ). The TERT promoter mutation and age 445 years were both associated with inferior OS (P ¼ 0.038 and 0.003, respectively, Figures 4a and b) , and the former failed to significantly affect OS, whereas the age effect remained in multivariate analysis (Figure 4c for TERT mutated and wild type: P ¼ 0.099, and Figure 4d for age 445 years and o45 years: P ¼ 0.023). Borderline significantly worse DRS was correlated with the TERT promoter mutation (Figure 4e , P ¼ 0.058) and age 445 years was significantly associated with DRS in univariate analysis (Figure 4f , P ¼ 0.019), however, both of them were unable to predict DRS independently, as revealed by the multivariate analysis ( Figure 4g for the TERT promoter mutation, P ¼ 0.124, and Figure 4h for age 445 years, P ¼ 0.08).
DISCUSSION
Recent studies have revealed the TERT promoter mutation in different types of human malignancies. [22] [23] [24] [25] In the present study, we determined the TERT promoter mutation in thyroid cancerderived cell lines and primary thyroid cancer specimens, and observed different mutation frequencies in the different types of thyroid cancer. The two MTC cell lines and 37 primary MTC tumors derived from parafollicular C cells were all negative for the TERT promoter mutation, whereas all follicular thyroid cell-originated cancers harbored the mutation with varying frequencies dependent on subtype: 50% in ATC (10/20), 25% in PTC (13/51) and 22% (8/36) in FTC, respectively. The highest mutation frequency (75%) was observed in ATC cell lines. During our submission of this study, Liu et al. published similar results. 27 TERT expression and telomerase activation maintain telomere length, thereby conferring cancer cells infinite proliferation potential. In addition to its telomere-lengthening function, TERT exhibits many other biological activities through which cancer progression is enhanced. [28] [29] [30] [31] Telomerase activity and TERT expression are widespread in human malignancies, and higher TERT expression was found to be correlated with advanced stages of cancer and poor patient outcomes. [32] [33] [34] The same scenario has Abbreviations: NS, not statistically significant; PTC, papillary thyroid cancer; TERT, telomerase reverse transcriptase. Significant P-values are indicated in bold.
TERT promoter mutation in thyroid cancer T Liu et al also been observed in thyroid cancer. 8, 9, 17, 21 Similar to the TERT expression profile reported above, the TERT promoter mutation frequency increased significantly from PTC and FTC to highly aggressive ATC. ATC patients with the TERT promoter mutation tended to survive shorter compared with those without the mutation. In PTC patients, the TERT promoter mutation was highly correlated with metastasis, and was a strong and independent factor to predict DRS. Age 445 years were correlated with worse OS, but did not predict DRS independently. We also found that FTC patients carrying the TERT promoter mutation exhibited substantially shorter OS and DRS. Collectively, the presence of the TERT promoter mutation may define a fraction of thyroid carcinoma patients with progressive disease and unfavorable outcome.
It is currently unclear what drives the TERT promoter mutations. Killela et al. 24 hypothesized that the TERT promoter mutation should occur more frequently in tumor types exhibiting high rates of alternating-lengthening of telomere. However, this is not the case in thyroid cancer. Widespread telomerase activation and TERT expression have been observed in ATC, PTC and FTC, and we identified the mutation at a high frequency in these tumors. In contrast, 40% of our MTC patients (15/37) are negative for TERT expression and alternating-lengthening of telomere is utilized to maintain telomere sizes in their tumors (unpublished results), and none of these tumors carried the TERT promoter mutation. Evidently, although being absent in parafollicular C cell-derived MTC, the mutations are exclusively present in follicular thyroid cell-derived cancer, which suggests cell type-and origindependent TERT promoter mutation in thyroid cancer. Moreover, the TERT promoter mutation rather than BRAF V600E was restricted to PTC patients 445 years old, highlighting the specific role of patients' age in the mutational event. Telomerase activity or TERT expression in human epithelial and other cells declines with increasing age from early adults, whereas telomere shortening occurs continuously during a lifetime. 5, 35 Conceivably, thyroid epithelial cells from later age possess shorter telomeres due to their progressive erosion, and when oncogenic events drive active proliferation of these thyroid cells with diminished telomerase activity, excessive loss of telomeres leads to telomere dysfunction or even telomere crisis. Too short telomeres or telomere crisis triggers genomic instability and pressures cells for telomerase activation, thereby causing TERT promoter mutations. In contrast, young individuals' thyroid epithelial cells have longer telomeres coupled with telomerase proficiency, and in such cases, their telomeres are likely long enough to avoid telomere crisis and telomerase may be upregulated via other pathways rather than the TERT promoter mutation. Consistent with this hypothesis, we did observe significantly shorter telomeres in PTCs harboring the TERT promoter mutation. Based on the present results together with published reports, we propose a model named the agingand telomere crisis-driven TERT promoter mutation in thyroid carcinogenesis ( Figure 5) .
To address the relationship between the mutation and radiation, we sequenced the TERT core promoter in tumors from 51 PTC patients who had been exposed to radioactivity from the accident at the Chornobyl nuclear power station in Ukraine in 1986, 26 but none of them carried C228T or C250T mutations. However, a similar frequency of the BRAF mutation (66%) was seen in this cohort of patients and they also exhibited other common genetic alterations as seen in PTC cases without radioactivity exposure elsewhere. 26 Of note, these patients were all young adults with age ranging from 19 to 39 years, which might explain the lack of TERT promoter mutation in accordance with our observation in the Swedish cohort of PTC patients. Collectively, radioactivity has a negligible role in the induction of the TERT promoter mutation in PTC.
In summary, we identified a high frequency of TERT promoter mutation in follicular thyroid cell-derived thyroid carcinomas. This genetic event is aging dependent and shorter telomere dependent. Importantly, our results reveal the TERT promoter mutation as a potential marker for thyroid cancer progression and outcome prediction. It should be worthwhile to prospectively analyze the clinical utility of these mutations further as a prognostic marker in thyroid cancer.
MATERIALS AND METHODS

Patients and tumor specimens
The study was conducted on 144 patients with thyroid cancer who were diagnosed and underwent surgery at Karolinska University Hospital Solna. These patients included 20 ATCs, 51 PTCs, 36 FTCs and 37 MTCs. The detailed clinical information for all studied patients with ATC, PTC or FTC is given in Supplementary Tables S1-S3. The specimens were collected after surgical treatment within the Karolinska University Hospital Biobank and kept frozen at À 70 1C until use. All samples were collected with informed consent and approval by the local ethics committee.
Tumors were diagnosed according to the criteria of the World Health Organization. Information was retrospectively collected concerning clinical characteristics including: gender, age at diagnosis, tumor size and other histopathological characteristics, and distant metastases. Cases were retrospectively followed-up for classification of outcome as: alive with disease; alive without signs of disease; dead of disease or dead without disease. 
Cell lines
Eight ATC-and two MTC-derived cell lines were examined for TERT promoter mutation as detailed in Supplementary Table S4. DNA extraction and sequencing Genomic DNA was extracted from frozen tumor tissue samples using standard methods.The two mutations defined as C228T and C250T in the TERT core promoter correspond to positions 124 and 146 bp upstream of ATG site (Figure 1a) . 22, 23 The target region was amplified by PCR using primers listed in Supplementary Table S5 , followed by Sanger sequencing. The C228T or C250T mutation was verified by sequencing from both directions. The same set of DNA from PTC and ATC specimens was also analyzed for BRAF V600E mutation by Sanger sequencing.
Telomere length assessment
Telomere length was assessed using a previously described quantitative PCR-based method. 36 The primer sequences for telomere (T) and b-globin (S) are given in Supplementary Table S5 . Relative telomere length was 
Statistical analyses
Mann-Whitney U-test was used to compare telomere length between different groups. The relationship between tumor telomere length and age was determined using Pearson analysis. Differences in the TERT promoter mutation frequency between tumors with different BRAF mutation statuses or clinical parameters were determined using Fisher's exact test. OS and DRS were illustrated by Kaplan-Meier plots, and significance was calculated by log-rank test. All the tests were two-tailed and computed using SigmaStat3.1 software (Systat Software, Inc., Richmond, CA, USA). P values of o0.05 were considered as statistically significant. Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc) Figure 5 . The aging-and telomere crisis-driven TERT promoter mutation during thyroid carcinogenesis. Normal thyroid epithelial cells (TECs) differ in telomere length and telomerase activity between young and later ages. TECs from young age are telomerase proficient ( þ ) with longer telomere, whereas those from later are telomerase deficient ( ± or -) with shorter telomere. When TECs are attacked by oncogenic events, they undergo active proliferation with further erosion of their telomere. In that case, telomere dysfunction or even telomere crisis occurs in later age TECs because of their initial shorter telomere and lack of telomerase activity. Telomere crisis triggers both genomic instability and telomerase activation: the TERT promoter mutation is thus the consequence of genomic instability, whereas in turn contributes to derepressing TERT transcription and telomerase activation. In contrast, young age TECs have certain levels of TERT/ telomerase activity and relatively longer telomere and when telomere dysfunction happens, telomerase is easily upregulated to prevent telomere crisis, thereby attenuating genomic instability or occurrence of the TERT promoter mutation.
